Anticipate generic drug launch
Find generic entry opportunities
Proactively manage your pharmacy inventory
Manage your formulary budget
Deep knowledge on
small-molecule drugs and
the 110,000 global patents
Drug patents …
… from Kazakhstan to Kalamazoo
Flat-rate pricing for predictable budgeting
Short-term plans for project- or client-based billing
Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing
|Title:||Alpha-heterocycle substituted tolunitriles|
|Abstract:||The invention is concerned with aromatase inhibiting compounds of formula I ##STR1## wherein R and Ro represent hydrogen or lower alkyl; or R and Ro located on adjacent carbon atoms and together when combined with the benzene ring to which they are attached form a naphthalene or tetrahydronaphthalene ring; R.sub.1 and R.sub.2 independently represent hydrogen, lower alkyl, (lower alkyl, aryl or aryl-lower alkyl)-thio, lower alkenyl, aryl, aryl-lower alkyl, C.sub.3 -C.sub.6 -cycloalkyl, or C.sub.3 -C.sub.6 -cycloalkyl-lower alkyl; or R.sub.1 and R.sub.2 combined represent lower alkylidene, mono-or di-aryl-lower alkylidene; R.sub.1 and R.sub.2 combined also represent C.sub.4 -C.sub.6 -straight chain alkylene, lower alkyl-substituted straight chain alkylene or ortho-phenylene bridged-C.sub.2 -C.sub.4 -straight chain alkylene, each forming with the carbon atom attached thereto a corresponding optionally substituted or benzo-fused 5, 6 or 7-membered ring; W represents 1-imidazolyl, 1-(1,2,4- or 1,3,4)-triazolyl or 3-pyridyl; or W represents 1-imidazolyl, 1-( 1,2,4 or 1,3,4)-triazolyl or 3-pyridyl substituted by lower alkyl; and pharmaceutically acceptable salts thereof.|
|Inventor(s):||Bowman; Robert M. (Summit, NJ), Browne; Leslie J. (Morristown, NJ)|
|Assignee:||Ciba-Geigy Corporation (Ardsley, NY)|
|Filing Date:||May 11, 1992|
|Claims:||1. A method for preparing a compound of the formula ##STR16## wherein R and R.sub.o represent hydrogen or lower alkyl; or R and R.sub.o located on adjacent carbon atoms and together when combined with the benzene ring to which they are attached form a naphthalene or tetrahydronaphthalene ting; R.sub.1 represents hydrogen; R.sub.2 represents 4-cyanophenyl; and W represents 1-(1,2,4)-triazolyl; which comprises condensing under basic conditions using an alkali metal aikoxide a compound of the formula XI ##STR17## wherein R, R.sub.o and W have meaning as defined above, with p-fluorobenzonitrile. |
2. A method according to claim 1 wherein the alkali metal alkoxide is potassium t-butoxide.
3. A method according to claim 1 for preparing 4-[alpha-(4-cyanophenyl)-1-(1,2,4-triazolyl)-methyl]benzonitrile which comprises condensing 4-[1-(1,2,4)-triazolylmethyl]benzonitrile with 4-fluorobenzonitrile using potassium tert-butoxide in dimethylformamide.
4. A process according to claim 1 for preparing 4-[alpha-(4-cyanophenyl)-1-(1,2,4-triazolyl)-methyl]benzonitrile.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.